Tarsus Pharmaceuticals Statistics
Share Statistics
Tarsus Pharmaceuticals has 42.01M
shares outstanding. The number of shares has increased by 10.13%
in one year.
| Shares Outstanding | 42.01M |
| Shares Change (YoY) | 10.13% |
| Shares Change (QoQ) | 8.84% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 54 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 7.78M, so 18.52% of the outstanding
shares have been sold short.
| Short Interest | 7.78M |
| Short % of Shares Out | 18.52% |
| Short % of Float | 19.15% |
| Short Ratio (days to cover) | 8.91 |
Valuation Ratios
The PE ratio is -18.02 and the forward
PE ratio is 35.18.
Tarsus Pharmaceuticals's PEG ratio is
0.54.
| PE Ratio | -18.02 |
| Forward PE | 35.18 |
| PS Ratio | 11.38 |
| Forward PS | 1.9 |
| PB Ratio | 9.27 |
| P/FCF Ratio | -24.61 |
| PEG Ratio | 0.54 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Tarsus Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.42,
with a Debt / Equity ratio of 0.32.
| Current Ratio | 4.42 |
| Quick Ratio | 4.39 |
| Debt / Equity | 0.32 |
| Debt / EBITDA | -0.68 |
| Debt / FCF | -0.86 |
| Interest Coverage | -15.36 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $566,417.96 |
| Profits Per Employee | $-357,752.32 |
| Employee Count | 323 |
| Asset Turnover | 0.49 |
| Inventory Turnover | 4.9 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 34.66% in the
last 52 weeks. The beta is 0.84, so Tarsus Pharmaceuticals's
price volatility has been higher than the market average.
| Beta | 0.84 |
| 52-Week Price Change | 34.66% |
| 50-Day Moving Average | 47.22 |
| 200-Day Moving Average | 44.27 |
| Relative Strength Index (RSI) | 45.64 |
| Average Volume (20 Days) | 684,753 |
Income Statement
In the last 12 months, Tarsus Pharmaceuticals had revenue of 182.95M
and earned -115.55M
in profits. Earnings per share was -3.07.
| Revenue | 182.95M |
| Gross Profit | 170.13M |
| Operating Income | -120.57M |
| Net Income | -115.55M |
| EBITDA | -106.48M |
| EBIT | -108.11M |
| Earnings Per Share (EPS) | -3.07 |
Full Income StatementBalance Sheet
The company has 94.82M in cash and 72.45M in
debt, giving a net cash position of 22.37M.
| Cash & Cash Equivalents | 94.82M |
| Total Debt | 72.45M |
| Net Cash | 22.37M |
| Retained Earnings | -360.21M |
| Total Assets | 500.75M |
| Working Capital | 394.46M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -83.03M
and capital expenditures -1.57M, giving a free cash flow of -84.59M.
| Operating Cash Flow | -83.03M |
| Capital Expenditures | -1.57M |
| Free Cash Flow | -84.59M |
| FCF Per Share | -2.25 |
Full Cash Flow StatementMargins
Gross margin is 92.99%, with operating and profit margins of -65.9% and -63.16%.
| Gross Margin | 92.99% |
| Operating Margin | -65.9% |
| Pretax Margin | -63.16% |
| Profit Margin | -63.16% |
| EBITDA Margin | -58.2% |
| EBIT Margin | -65.9% |
| FCF Margin | -46.24% |
